Drugs / CARLECORTEMCEL-L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01484470 | Jan 2010 → Nov 2018 | hematopoietic and lymphoid cell neoplasm | Loyola University | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00469729 | Oct 2007 → Feb 2013 | Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia, lymphoid leukemia +2 | Gamida Cell -Teva Joint Venture Ltd. | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-11-06 | Teva Branded Pharmaceutical Products R&D, Inc. | First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma tevapharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARLECORTEMCEL-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107845 ↗ |
| Known as | StemEx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01484470 ↗ |
| Modality | Cell therapy | “The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells” NCT00469729 ↗ |
| Route | Other | “which is infused to subject at a rate of 1-3 ml/min” NCT00469729 ↗ |